LL-37 vs. TA-1 for immune support: what the research actually shows

What's this video probably claiming?

Based on the caption and hashtag context, this creator is likely walking viewers through a comparison of two peptides with immune-modulating properties: LL-37, a human antimicrobial peptide, and Thymosin Alpha-1 (TA-1), a thymic peptide. The creator appears to be positioning both as immune support tools in the biohacking space, and makes specific mention that TA-1 is FDA-approved in certain clinical settings. Given the seasonal framing and the wellness hashtags, the video is probably arguing that these peptides offer research-backed immune benefits worth knowing about. The creator seems to be responding to a common audience question about which peptide is better for immune function, which is a question that sounds straightforward but opens a genuinely complicated regulatory and scientific can of worms.

What does the science actually show?

LL-37 is a cathelicidin-derived antimicrobial peptide that the body produces naturally, particularly in epithelial cells and neutrophils. Research confirms it plays a legitimate role in innate immunity. A 2016 study by Fabisiak et al. in the Journal of Immunology Research documented LL-37's anti-inflammatory and immunomodulatory properties in epithelial contexts. However, exogenous LL-37 administration in humans is poorly studied. Most data comes from in vitro or murine models. Thymosin Alpha-1 has a more substantial human trial record. It is the active ingredient in Zadaxin, which has regulatory approval in over 35 countries for hepatitis B, hepatitis C, and as an adjunct in cancer immunotherapy. A 2020 meta-analysis by Liu et al. in Clinical and Translational Medicine covering 23 randomized controlled trials found TA-1 improved immune markers and outcomes in sepsis patients. The two peptides work through different mechanisms, and comparing them as interchangeable immune tools flattens that distinction significantly.

Where does the social media noise diverge from clinical reality?

The creator's framing of TA-1 as FDA-approved deserves close scrutiny. Thymalfasin (Zadaxin) is not FDA-approved in the United States. It has received Orphan Drug designation for certain indications, but that is not the same as full approval. Calling it FDA-approved without that qualifier is misleading. As for LL-37, there is essentially no human clinical trial data supporting its use as an administered peptide for immune support. A 2021 review by van Harten et al. in Frontiers in Immunology specifically noted that while LL-37 is biologically active endogenously, its therapeutic application faces significant delivery and stability challenges. Biohacking communities routinely collapse the distance between endogenous biological activity and the effects of externally administered compounds, and this video appears to follow that pattern. The seasonal wellness framing adds a layer of implied efficacy that the research does not yet support for either compound outside controlled clinical contexts.

What should you actually know?

If you are genuinely interested in immune-modulating peptides, the evidence base is not symmetrical between LL-37 and TA-1. TA-1 has real clinical trial data, meaningful safety records from international use, and plausible mechanisms involving T-cell maturation and dendritic cell activation, as outlined in a 2019 review by Romani et al. in Expert Opinion on Biological Therapy. LL-37, while genuinely important in human biology, does not have a comparable evidence base for exogenous use. Neither peptide has been demonstrated to prevent seasonal illness in healthy adults, which appears to be the implied use case here. In the United States, both compounds exist in a regulatory gray zone when compounded. No compounded peptide has demonstrated bioequivalence to clinically studied formulations. Anyone considering these compounds should have that conversation with a licensed provider who understands the current FDA compounding guidance, not a TikTok comparison video.